Atlas Special Opportunities

Acheter-Louer.fr is a company that focuses on internet-based real estate services, providing a platform for buying, selling, renting, and leasing properties. It specializes in publishing small professional real estate advertisements, catering to both individuals and real estate professionals. Through its online services, Acheter-Louer.fr aims to facilitate property transactions by connecting buyers, sellers, and renters in a streamlined manner. The company's offerings contribute to the evolving landscape of real estate, leveraging digital solutions to meet the needs of its users.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing innovative ophthalmic therapies aimed at preserving vision in patients with retinal vascular disorders. The company targets conditions such as diabetic macular edema, which is the leading cause of vision loss among diabetic patients, as well as wet age-related macular degeneration and retinal vein occlusion. Through its advanced research and development initiatives, Oxurion seeks to create next-generation treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing innovative ophthalmic therapies aimed at preserving vision in patients with retinal vascular disorders. The company targets conditions such as diabetic macular edema, which is the leading cause of vision loss among diabetic patients, as well as wet age-related macular degeneration and retinal vein occlusion. Through its advanced research and development initiatives, Oxurion seeks to create next-generation treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing innovative ophthalmic therapies aimed at preserving vision in patients with retinal vascular disorders. The company targets conditions such as diabetic macular edema, which is the leading cause of vision loss among diabetic patients, as well as wet age-related macular degeneration and retinal vein occlusion. Through its advanced research and development initiatives, Oxurion seeks to create next-generation treatments that enhance the standard of care for these debilitating eye diseases.

Oxurion is a clinical-stage biopharmaceutical company based in Belgium, focused on developing innovative ophthalmic therapies aimed at preserving vision in patients with retinal vascular disorders. The company targets conditions such as diabetic macular edema, which is the leading cause of vision loss among diabetic patients, as well as wet age-related macular degeneration and retinal vein occlusion. Through its advanced research and development initiatives, Oxurion seeks to create next-generation treatments that enhance the standard of care for these debilitating eye diseases.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.

Drone Volt SA is a manufacturer and distributor of professional civilian drones, headquartered in Villepinte, France. Established in 2011, the company operates in multiple countries, including Belgium, the Netherlands, Canada, Denmark, the United States, Switzerland, and Indonesia. Drone Volt provides a range of commercial drones designed for various applications such as inspection, surveillance, thermography, and search and rescue missions, targeting sectors like energy, construction, security, and agriculture. In addition to its own drone products, the company also distributes DJI drones and accessories for civil and commercial use. Drone Volt offers a comprehensive suite of services, including engineering consulting, aerial data acquisition, professional drone training, maintenance, and legal support. The company serves a diverse clientele, including government agencies and industrial groups, while also exporting its products globally.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

TME Pharma is a clinical-stage biopharmaceutical company focused on enhancing cancer treatment by targeting the tumor microenvironment. The company develops biostable aptamers and mirror image nucleic acids, with its leading products, NOX-A12 and NOX-E36, classified as Spiegelmers. This innovative class of drugs offers specific advantages over traditional therapies, aiming to improve the effectiveness of cancer treatments. TME Pharma has also established a strategic alliance with Pfizer, Inc. The company is headquartered in Berlin, Germany, and is dedicated to advancing its research to benefit patients battling cancer.

Circio Holding ASA is a clinical-stage biotechnology company dedicated to developing and commercializing immuno-oncology therapies aimed at treating resistant solid tumors. The company's lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus designed to infect cancer cells and stimulate the immune system's response against tumors. In addition to ONCOS-102, Circio is advancing other candidates in its pipeline, including circVec and Mutant KRAS, which focus on targeted immunotherapy treatments for cancer patients. The company's innovative approach leverages cutting-edge genetic engineering to enhance the efficacy of cancer treatments, with a commitment to addressing the challenges posed by treatment-resistant cancers.